NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.385) was uploaded to the NHS England Website on Monday 26, January 2026.
The following changes have been introduced:
Niraparib (NIR3) ## Niraparib (NIR3)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation (TA673) where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Recommended for routine commissioning, receiving CDF interim funding - column N updated Recommended for routine commissioning, receiving CDF interim funding - column N updated
Niraparib (NIR3) ## Niraparib (NIR3)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation (TA673) where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Recommended for routine commissioning, receiving CDF interim funding - column N updated Recommended for routine commissioning, receiving CDF interim funding - column N updated
Apalutamide in combination with androgen deprivation therapy (ADT) (APA2)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are ineligible for chemotherapy with docetaxel where the following criteria have been met
Treatment criterion (#8) updated
Darolutamide in combination with androgen deprivation therapy (ADT) (DARO3)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel where the following criteria have been met
Treatment criterion (#8) updated
Enzalutamide in combination with androgen deprivation therapy (ADT) (ENZ3)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer where the following criteria have been met
Treatment criterion (#7) updated